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Abstract 
Influenza is a virus that affects people of all ages; and thus, recommendations indicate 
starting vaccinations: at the age of six months. However, within the population there lies a group 
of vulnerable people that includes elderly adults. Elderly adults are a population at high risk for 
poor outcomes related to influenza as they are frailer and have a lower immune response to the 
influenza vaccination. This paper includes a case report of is on a 56 year old Caucasian man 
who presented to the clinic with symptoms that were found to be related to influenza. The rapid 
influenza swab revealed positive influenza and the client was noted to be on methotrexate for his 
arthritis, which can compromise one’s immune system. He was noted to be updated on his 
influenza vaccination, but over the recommended two days of illness onset to when treatment 
with anti-viral should be administered. Influenza vaccinations remain an important and effective 
health measure in helping reduce poor outcomes such as hospitalizations and mortality in elderly 
adults. Recent research about the effectiveness of influenza vaccinations has been put into 
question. Frailty and vaccine effectiveness in the elderly were found to have a correlation. This is 
an important finding as addressing frailty in the elderly has led to the research of using high-dose 
vaccination to help improve immune responses. Clinicians should take into account frailty and 
the possibility of using high-dose vaccinations in the elderly to improve their outcomes.  
Keywords: Frailty, influenza, vaccination, effectiveness  
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Influenza Vaccine Effectiveness in the Elderly  
Background 
Influenza is a communicable illness that can be fatal and lead to significant 
hospitalizations in vulnerable groups, such as the elderly, pregnant women, and clients with 
chronic conditions (Lee, Chen, Tang, & Lan, 2014). Most every winter an influenza epidemic 
occurs, causing about 5 to 20 percent of people to become ill (Lee, Chen,  Tang, & Lan, 2014). 
Illnesses due to influenza lead to approximately 300,000 hospitalizations and 36,000 deaths 
annually (Lee, Chen, Tang, & Lan, 2014).  However, during a pandemic season around 90 
percent of deaths occur in people 65 years or older (Lee, Chen, L., Tang, G., & Lan, T, 2014). 
In order to avoid the influenza disease and its negative consequences, the main approach 
for prevention of seasonal outbreaks is vaccinating, making influenza a vaccine-preventable 
disease (Lee, Chen, Tang, & Lan, 2014). This mainstay approach to prevention is universally 
recommended for the elderly population, however, evidence to support that vaccinations in the 
elderly reduce influenza related mortality is insufficient (Simonsen et al., 2007). Many trials 
indicate that vaccinations help to prevent influenza illness in the young and healthy elderly 
population. However, no data from studies show benefits for those 70 years and older and this 
age group accounts for most influenza- related deaths (Simonsen et al., 2007). The efficacy and 
effectiveness of vaccination for influenza remains uncertain due to this sparse evidence derived 
from healthy young adults. The evidence for vaccine effectiveness (VE) in frail elderly is even 
less (Lee, Chen, Tang, & Lan, 2014). 
According to Simonsen et al. (2007) effectiveness of the influenza vaccine in elderly 
nursing home clients actually declines when combined with developing functional impairment. 
This indicates that frailty could be associated with vaccine-induced antibody responses (Lee, 
Chen, Tang, & Lan, 2014). It was found that the VE within the elderly especially those 65 years 
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and older had a large VE gap when confirmed against laboratory influenza results. This range 
was between 33 to 86 percent and this inconsistency has led to discussion about whether the 
influenza vaccine benefits elderly people against potential severe outcomes such as 
hospitalizations or mortality (Lee, Chen, Tang, & Lan, 2014).   
Case Report 
MA is a 56 year old male who presented to the clinic in January of 2018 with complaints 
of fever, chills, cough, joint pain and fatigue for past the five days. MA denied being around 
anyone who was currently sick, and denied any travel out of the country. He stated he had no 
nausea, vomiting, loss of appetite, or diarrhea. He reported generalized aches and pains. His 
cough was mostly nonproductive. He denied any hemoptysis or discolored sputum. He had no 
chest pain and no shortness of breath. He reported the use of ibuprofen 400mg every four to six 
hours for generalized aches. He reported he did not check his temperature at home but felt the 
chilled.    
Upon evaluation, MA’s medical history included rheumatoid arthritis and hypertension. 
He had no past surgical history and no known allergies. Medications included lisinopril, Humira, 
Methotrexate injections, and a multivitamin. His social history included no tobacco use and he 
reported drinking a glass of wine once or twice a week. He was also up to date on his influenza 
vaccine. Upon physical examination, vital signs included blood pressure 142/92, heart rate 90, 
respirations 30, and temperature 102.4 degrees Fahrenheit. In general the patient looked unwell, 
but in no acute distress.  Head, ear, eyes, nose and throat exam (HEENT) revealed his head to be 
atraumatic and normocephalic. Pupils were equal, round, and reactive to light. Extraocular 
movements were intact. There was no icterus, cyanosis, or pallor of the conjunctivae. His 
bilateral ear exam including the pinna, tragus, and external canal non-tender. His ear canal and 
tympanic membranes were translucent and mobile. Nose inspection revealed pink nasal mucosa, 
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septum midline and patent nares bilaterally. Throat inspection presented an oropharynx with no 
erythema or exudate. Along with moist mucous membranes, no thrush, no lesions, and good 
dentition were noted. The neck was supple and trachea was midline. No cervical 
lymphadenopathy present upon examination. The chest examination revealed adequate air 
exchange bilaterally, no crackles, wheezes or rhonchi were appreciated. Heart sounds one, and 
two heard, and no murmurs or gallops present with regular rate and rhythm. No murmurs, 
gallops, or rubs were noted. 
A diagnostic workup included a complete blood count with differential and 
nasopharyngeal influenza swab. Pertinent laboratory results included a positive rapid influenza 
antigen test and white blood cell count (WBC) was 9.7. MA was informed that he was positive 
for influenza; however, he was past the recommended two days of illness onset when treatment 
with an anti-viral should be administered. He was offered prescription cough syrup with codeine 
5mL by mouth three times a day for seven days if needed, given a dose of Tylenol 650mg prior 
to leaving the clinic, and rechecked temperature upon discharge. The patient was instructed to 
take Tylenol as needed for aches and pain, to drink many liquids, and stay home and rest. Also 
the patient was informed to not exceed recommended daily dosage of Tylenol. If he did not get 
any better, the client was informed to come back to the clinic for further evaluation such as chest 
x-ray and more lab work. Education on vaccinations was provided because MA is entering the 
spectrum of old age and has multiple comorbidities, thus it is imperative that he stays up to date 
on his yearly influenza vaccine. Older adults with multiple chronic medical conditions are at 
more risk for serious illness and even death. 
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Literature Review 
The body of evidence found for this literature search was broad. Literature found was 
based on different aspects of evidence including previous studies done on vaccine effectiveness 
of the elderly, assessment of frailty, and the comparison of vaccine effectiveness for influenza. 
The interventions and outcomes that were used to measure this search were diverse.  
Furthermore, none of these studies assessed a placebo-controlled study or randomized control 
trials, as this would be unethical. 
A search strategy was conducted using the University of North Dakota’s Harley French 
medical library. Three different search engines were used in an attempt to search for information 
and included CINAHL, PubMED, and Clinical Key. The Keywords used were associated with 
the interventions and included that of influenza vaccine, elderly and/or aged, effectiveness and 
mortality. 
The literature search on the topic of vaccine effectiveness in reducing mortality in the 
elderly compared to elderly who did not receive the vaccine lead to a wide range of results. 
Consequently, the articles reviewed had a variety of interventions and means of research. This 
led to the inclusion of comparing different variations in influenza vaccines, and if one vaccine 
maybe more beneficial than the other. The consensus was that VE does diminish with increased 
ageing and that frailty has an astounding effect on VE. Moreover, vaccination still remains an 
important intervention for influenza, as it is associated with a reduction in hospitalizations and 
adverse outcomes for the elderly.  
An important aspect to account for in the ageing process is frailty. Frailty is considered a 
measure of health, function, and vulnerability and can predict health outcomes often better than 
age alone (Andrew et al., 2017; Simonsen et al., 2007). Therefore, frailty is an important 
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contender that should be addressed when measuring VE. However, in most proposed studies on 
the influenza vaccine, it is inadequately regarded. (Andrew et al., 2017). Frailty can often be 
difficult to assess in patient charts as it is calculated by addressing an accumulation of deficits in 
health using the frailty index (FI). Deficits in health can be signs and symptoms of diseases, 
disability, and laboratory, electrocardiographic, or radiographic abnormalities. As a patient 
accumulates more of these deficits, they are more likely to be considered frail. The FI generally 
is disclosed as a ratio of deficits present compared to the number of deficits considered (Searle, 
Mitnitski, Gahbauer, Gill, & Rockwood, 2008). 
 Andrew et al. (2017) performed a case-control study to assess VE in the elderly adult 
with a focus on frailty. The authors concluded that VE does display differences among non-frail 
elderly adults and frail older adults in that VE was very good (77.6%) among nonfrail elderly, 
lower in prefrail elderly, and was all most nonexistent in most frail elderly. This study indicated 
that frailty assessment is important as it addresses function status in the over-all health status of 
patients. 
 Mannino et al.( 2012) included an observational study that compared the vaccines MF59 
adjuvant trivalent inactivated vaccine (ATIV), versus the nonadjuvanted trivalent inactive 
vaccine (TIV) in elderly 65 years and older. ATIV was used as a comparison to the standard 
vacation because it was established for the elderly population to help increase their immune 
responses to the influenza vaccination. In this study, it was found that the elderly who received 
ATIV had more baseline hospitalization due to frailty; however, the study still found that those 
who obtained ATIV had a twenty-five percent risk reduction of hospitalization during peak 
influenza season than elderly who received TIV. 
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 Similarly, a study done by Domnich, Arata, Amicizia, Puig-Barbera & Gasparini (2017) 
executed a systematic review of observational studies to find out if using an adjuvant (MF59-
TIV) would help to increase vaccine potency; thus allowing, a more rapid and broader immune 
response in the elderly. These particular authors assessed the adjuvant MF59 which has 
demonstrated immuno-stimulatory proprietaries such as activating local immune cells at the 
injection site and promoting transition of monocytes to dendritic cells. This analysis of adjuvants 
holds value for the elderly as people begin to age; it can consequently cause a reduction in innate 
and adaptive humoral and T-cell mediated immunity (Andrew et al., 2017). This is a normal 
process of age-related decline and reduces one’s ability to fight off the influenza infection. This 
process of ageing is known as immunosenescence (Andrew et al., 2017). The authors of this 
article assessed observational studies, which are great resources to look at vaccine effectiveness 
in the field, and found that VE with MF59-TIV reduced hospitalizations for pneumonia/influenza 
by more than 50 percent and is an effective vaccine at reducing influenza related outcomes in the 
elderly.  
In another article by DiazGranados et al. (2014)  a high dose vaccine (IIV3-HD) 
compared to the standard-dose vaccine (IIV3-SD)  enhanced antibody responses against 
influenza in people 65 years or older. They found similar results in that a higher dose vaccine did 
in fact provide enhanced protection against confirmed influenza illness.  
The theory of high dose vaccination holds value in another study by Nace et al. (2015) 
who found that in the frail elderly, high dose vaccination produced higher-level responses for 
almost every strain of influenza. In this literature search, this was the only study found that 
performed a randomized control trial (RCT) within long-term care facilities on clients 65 years 
or older. The study compared standard dose influenza vaccines versus high dose vaccinations. In 
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order to compare the two vaccines blood samples were obtained and analyses of geometric mean 
titers (GMT) were used as the outcome.  Using this means, the study found that in frail older 
adults the GMT’s were higher with the high dose vaccination indicating an enhanced immune 
response.   
In an additional study by Wilkinson et al. (2017), a systematic review was conducted to 
determine whether higher-dose vaccines of influenza were more effective and usage was safe in 
the elderly aged 65 years or older. Their theory was that elderly are more pressured to receive the 
influenza vaccine to help reduce poor outcomes; however, they are prone to having lower 
antibody reaction to vaccines rendering them less effective. Thus, raising the dose of influenza 
antigens may increase their immune response and enable the vaccine to be more effective. The 
outcome addressed in this study did not look at reduction in mortality, but rather a reduction in 
laboratory-confirmed illness. When addressing this outcome, it was found that the elderly whom 
received a high-dose influenza vaccine had a 24 percent reduction in the risk of laboratory-
confirmed influenza compared to those who received the standard-dose vaccine. The evidence 
that high-dose vaccinations are effective at reducing the amount of influenza cases is paramount 
as a study by Jefferson et al. (2005), whom performed a search of electronic databases, found 
that VE of trivalent influenza vaccines had a minimal effect on the reduction of cases within the 
elderly population. Nevertheless, the standard dose of the influenza vaccination proved to have a 
better impact on complications of influenza such as hospitalizations and all-cause mortality 
rather than cases of influenza. 
Thomas (2014) who also performed a systematic review found the outcome of mortality 
often was an all-cause mortality, which is a non-specific outcome and can be subject to unknown 
biases. He concluded that specific outcomes would be more applicable if they included 
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laboratory-proven influenza or pneumonia deaths. Moreover, the author found that influenza 
associated death for those greater than 80 years of age was 11 times higher than the elderly ages 
65-69 and that these numbers continued to remain true even with increasing vaccination rates 
and vaccine match. In this randomized control study, the author found evidence that vaccine 
efficacy does in fact decrease with increasing age.  
 Campitelli, Rosealla, Stukel & Kwong (2011) conducted a cohort study to estimate the 
effectiveness of influenza vaccines in the elderly and whether it helps to reduce all-cause 
mortality. These authors wrapped up this literature search with the convincing evidence that 
elderly who receive an influenza vaccine are 39 percent less likely to die from any cause during 
influenza season when compared to non-vaccinated elderly. In addition to this evidence, they 
discovered that vaccinated individuals were also 45 percent less likely to die during pre-
influenza season and 26 percent less likely to die during post-influenza season. This indicates 
that not only does the influenza vaccine help reduce mortality, but it also has the presence of 
residual confounding effects during times when the influenza virus is not circulating.  
Throughout this search, there was one article which found that biases do exist within 
research studies and do affect outcomes within the elderly. An article by Wong, Campitelli, 
Stukel, & Kwong (2012) whom performed a cohort study over nine influenza seasons used 
instrumental variable (IV) analysis. IV analysis is a method of analysis that has been found to 
remove hidden bias in observational studies. This study using logistic regression found that 
adults 65 years and older who received an influenza vaccination demonstrated a reduction in 
both hospitalizations and mortality (33%) during influenza season and significant reduction in 
mortality after influenza season. However, when using IV analysis, which adjusted the 
association of influenza vaccination mortality during the influenza season, analysis expressed no 
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significance between the two seasons. These results also held true of IV analysis of post-
influenza vaccination.  
Through this research it confirmed that with age comes a decrease in vaccine 
effectiveness ranging from 17 to 60 percent, and that biases do exist within the research of VE in 
the elderly (Nace et al., 2015).  Influenza combined with pneumonia ranks as the eighth leading 
cause of death and is the number one vaccine preventable death in the United States. A goal of 
Healthy People 2010 is to have residents in long term care facilities reach an immunization goal 
of 90 percent for both influenza and pneumonia (Nace et al., 2015). This is imperative for the 
elderly and especially those in long-term care facilities as they are more exposed to the influenza 
virus, have reduced immune responses, and increased mortality rates compared to other 
populations (Nace et al., 2015). An important indicator to help assess if one is in need of a 
vaccination, especially a high-dose vaccination, is frailty and most often this incompletely 
captured in the health record. Frailty is an important confounder to address when assessing VE in 
the elderly as a lack of assessment can lead to underestimating VE in this specific population 
(Nace et al., 2015). In addition, if frailty assessment is overlooked for this population it can be 
considered frailty bias. The value of the influenza vaccination remains high as vaccinations for 
this particular age have been shown to reduce poor outcomes and proven to be the most cost 
effective health measure in reduction of the influenza virus.   
Learning Points 
• The best way to accomplish the Healthy People goal, as proven by presented research is 
with the use of high-dose vaccines to help produce a stronger immune response in the 
elderly. 
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• Assessment of frailty is important as the impact of influenza VE varies from very good in 
a healthy adult to almost nonexistent in the frail elderly (Nace et al., 2015).  
• Interventions for providers to help improve rates of vaccination include the use of 
reminders for patients; such as, reminder postcards or a phone call. To help increase 
access to influenza vaccinations providers and clinics could promote group visits or make 
home visits.  
• A second option could be to place facilitators in clinics alongside health professionals to 
help with education about influenza and influenza vaccinations to the patients and their 
caregivers (Thomas, Russel & Lorenzetti, 2010)..  
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